CN109507427B - 一种基于高亲和力cd45兔单抗的循环肿瘤细胞高效富集方法及其应用 - Google Patents
一种基于高亲和力cd45兔单抗的循环肿瘤细胞高效富集方法及其应用 Download PDFInfo
- Publication number
- CN109507427B CN109507427B CN201710826039.2A CN201710826039A CN109507427B CN 109507427 B CN109507427 B CN 109507427B CN 201710826039 A CN201710826039 A CN 201710826039A CN 109507427 B CN109507427 B CN 109507427B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- mab
- antibody
- blood
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 81
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 20
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 title claims abstract description 13
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 title claims abstract description 13
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 210000004027 cell Anatomy 0.000 claims abstract description 40
- 239000011324 bead Substances 0.000 claims description 61
- 210000004369 blood Anatomy 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 28
- 210000003743 erythrocyte Anatomy 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 18
- 210000005259 peripheral blood Anatomy 0.000 claims description 17
- 239000011886 peripheral blood Substances 0.000 claims description 17
- 210000002381 plasma Anatomy 0.000 claims description 16
- 238000011534 incubation Methods 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 108010090804 Streptavidin Proteins 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 9
- 102100035716 Glycophorin-A Human genes 0.000 claims description 8
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 7
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 claims description 7
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 7
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 7
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 230000017531 blood circulation Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 210000005266 circulating tumour cell Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 description 25
- 239000000243 solution Substances 0.000 description 20
- 238000001514 detection method Methods 0.000 description 17
- 238000000926 separation method Methods 0.000 description 15
- 238000004140 cleaning Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 11
- 210000000601 blood cell Anatomy 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000007664 blowing Methods 0.000 description 9
- 239000006059 cover glass Substances 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 238000000432 density-gradient centrifugation Methods 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000020584 Polyploidy Diseases 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本发明 | 对照 | |
CTC检出平均数(个/mL) | 0.93 | 0.82 |
残余白细胞数(个) | 392.3 | 23120.3 |
残余白细胞数(个/mL) | 65.4 | 3853.4 |
CTC检出率(例/例) | 15/15 | 11/15 |
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710826039.2A CN109507427B (zh) | 2017-09-14 | 2017-09-14 | 一种基于高亲和力cd45兔单抗的循环肿瘤细胞高效富集方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710826039.2A CN109507427B (zh) | 2017-09-14 | 2017-09-14 | 一种基于高亲和力cd45兔单抗的循环肿瘤细胞高效富集方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109507427A CN109507427A (zh) | 2019-03-22 |
CN109507427B true CN109507427B (zh) | 2022-05-31 |
Family
ID=65744434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710826039.2A Active CN109507427B (zh) | 2017-09-14 | 2017-09-14 | 一种基于高亲和力cd45兔单抗的循环肿瘤细胞高效富集方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109507427B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104178454A (zh) * | 2013-05-24 | 2014-12-03 | 益善生物技术股份有限公司 | 一种循环肿瘤细胞的富集、分析方法 |
CN105067808A (zh) * | 2015-07-30 | 2015-11-18 | 南京医科大学 | 一种高纯度循环肿瘤细胞的富集方法及试剂盒 |
CN106635995A (zh) * | 2017-03-10 | 2017-05-10 | 亚能生物技术(深圳)有限公司 | 一种循环肿瘤细胞阴性富集方法 |
CN106701684A (zh) * | 2016-12-19 | 2017-05-24 | 毕国明 | 一种高效率循环肿瘤细胞富集方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006018595D1 (de) * | 2005-04-08 | 2011-01-13 | Medical Discovery Partners Llc | Verfahren zum anreichern von subpopulationen seltener zellen aus dem blut |
CN103091491B (zh) * | 2011-11-01 | 2015-01-07 | 李彦萍 | 鉴别从人或动物生物体液中富集的非血源性有核细胞的方法 |
-
2017
- 2017-09-14 CN CN201710826039.2A patent/CN109507427B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104178454A (zh) * | 2013-05-24 | 2014-12-03 | 益善生物技术股份有限公司 | 一种循环肿瘤细胞的富集、分析方法 |
CN105067808A (zh) * | 2015-07-30 | 2015-11-18 | 南京医科大学 | 一种高纯度循环肿瘤细胞的富集方法及试剂盒 |
CN106701684A (zh) * | 2016-12-19 | 2017-05-24 | 毕国明 | 一种高效率循环肿瘤细胞富集方法 |
CN106635995A (zh) * | 2017-03-10 | 2017-05-10 | 亚能生物技术(深圳)有限公司 | 一种循环肿瘤细胞阴性富集方法 |
Non-Patent Citations (2)
Title |
---|
MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment;Morten Lapin等;《Scientific Reports》;20160719;第6卷;第1-10页 * |
Morten Lapin等.MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment.《Scientific Reports》.2016,第6卷第1-10页. * |
Also Published As
Publication number | Publication date |
---|---|
CN109507427A (zh) | 2019-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109991410B (zh) | 一种含抗cd45单抗的组合物及其使用方法 | |
DK2542689T3 (en) | Method for isolating target cells | |
US20020164825A1 (en) | Cell separation matrix | |
US10365266B2 (en) | Molecular characterization of circulating tumor cells | |
WO2015101163A1 (zh) | 抗hla-g的单克隆抗体偶联免疫磁珠在肿瘤细胞分选中的应用 | |
CN109856388A (zh) | 循环肿瘤细胞的捕获方法及捕获试剂盒 | |
CN106244553A (zh) | 循环肿瘤细胞的分离和检测方法 | |
CN106970225B (zh) | 一种应用cd45免疫荧光联合cep 8探针鉴定循环肿瘤细胞的试剂盒及其应用 | |
CN109777775A (zh) | 一种循环肿瘤细胞分离方法 | |
CN204086278U (zh) | 用于检测外周血循环肿瘤细胞的试剂盒 | |
CN111351937A (zh) | 一种mmr蛋白表达缺失检测试剂盒及其检测方法 | |
CN115651076B (zh) | 人骨髓间充质干细胞来源凋亡囊泡的表面标志物及其应用 | |
CN112920999B (zh) | 一种体外培养乳腺癌循环肿瘤细胞的方法 | |
CN109507427B (zh) | 一种基于高亲和力cd45兔单抗的循环肿瘤细胞高效富集方法及其应用 | |
CN110927369A (zh) | 一种利用tcpp联合cep探针鉴定循环肿瘤细胞的试剂盒及应用 | |
CN109439624B (zh) | 一种用于识别或富集有核红细胞的方法 | |
CN113125738A (zh) | 循环肿瘤细胞的检测方法 | |
CN110628721A (zh) | 一种循环肿瘤细胞的分离培养方法及试剂盒 | |
CN114381491A (zh) | 一种神经母细胞瘤相关的肿瘤细胞标志物及其应用 | |
CN108872603B (zh) | 一种用于肝癌干细胞的鉴定方法 | |
CN109781975B (zh) | 富集循环稀有细胞的试剂及方法 | |
WO2003035888A1 (en) | Cell separation matrix | |
CN114891106B (zh) | 共表达CD45和EpCAM的细胞群的检测和分离方法及其用途 | |
JP2018157812A (ja) | 試料中に含まれる細胞の検出方法 | |
CN117805376B (zh) | CD44和Lgr5作为标记物在筛选胃癌肿瘤干细胞中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 201805 floor 1, building 7, No. 1585, Yuanguo Road, Anting Town, Jiading District, Shanghai Patentee after: SHANGHAI BAIZE MEDICAL LABORATORY Co.,Ltd. Country or region after: China Patentee after: SHANGHAI CELL THERAPY Research Institute Patentee after: Shanghai Cell Therapy Group Co.,Ltd. Address before: 201805 floor 1, building 7, No. 1585, Yuanguo Road, Anting Town, Jiading District, Shanghai Patentee before: SHANGHAI BAIZE MEDICAL LABORATORY Co.,Ltd. Country or region before: China Patentee before: SHANGHAI CELL THERAPY Research Institute Patentee before: SHANGHAI CELL THERAPY GROUP Co.,Ltd. |
|
CP03 | Change of name, title or address |